INDENA Indena’s integrated CDMO platform for HPAPIS and ADCS provides momentum for growth, complexity and the outsourcing imperative. Highly potent active pharmaceutical ingredients (HPAPIs) are no longer a niche. They are at the centre of modern pharmaceutical innovation. As oncology, targeted therapies and precision medicine continue to reshape global pipelines, the demand for high-potency compounds is accelerating at a sustained pace. Independent market analyses consistently describe a robust and expanding HPAPI market, valued in the upper tens of billions of dollars and projected to grow steadily into the early 2030s. Within this scenario, the HPAPI CDMO segment is outpacing the broader API outsourcing market. The reason is clear: the technical, safety and regulatory complexity of handling ultrapotent compounds has raised the threshold for in-house manufacturing. Oncology dominates HPAPI utilisation, accounting for roughly two-thirds to three-quarters of applications. The continued rise of antibody-drug conjugates (ADCs), small molecule warheads, steroidal hormones and other selective compounds requiring occupational exposure limits (OELs) below 10 µg/cu m – and in some cases down to the nanogram range – is reshaping expectations around containment, engineering controls and process integration. In this environment, clients are not simply looking for capacity. They are seeking partners with measurable high-containment performance, scalable infrastructure, regulatory credibility and the ability to integrate complex chemistries under one roof. This is precisely the space where Indena has built its distinctive CDMO proposition. A century of expertise Founded in 1921, Indena has long been recognised for its expertise in active ingredients derived from medicinal plants for the pharmaceutical, nutraceutical and cosmetic industries. Over the decades, this heritage has evolved into a broader and highly specialised competence in the development and manufacturing of complex molecules, including highly potent APIs and ADC payloads. Today, Indena operates multiple GMP-certified sites in Italy and France, with its principal CDMO hub located in Settala, near Milan. The Italian facilities operate under EU GMP with AIFA approval, supported by system certifications such as ISO 14001 and ISO 45001, and a regulatory team experienced in interactions with global 42 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026
RkJQdWJsaXNoZXIy MjY2OTA4MA==